PTC Therapeutics acquires Sangamo's Fabry disease gene therapy for $211M in bankruptcy auction

PTC Therapeutics has won a competitive bankruptcy auction to acquire Sangamo Therapeutics' experimental Fabry disease gene therapy, ST-920, for $111 million in cash up front and up to $100 million in regulatory milestones. Sangamo, which filed for Chapter 11 bankruptcy in June 2026, also sold neurology assets to Eli Lilly for $50 million. PTC plans to complete the rolling FDA submission for ST-920 in Q4 2026, targeting a commercial launch in 2027. Analysts view the acquisition as a highly favorable, low-risk entry into the $2 billion Fabry disease market.

PTC acquires ST-920 therapy

• ▪PTC Therapeutics expects to complete the acquisition of ST-920 late in the third quarter or early in the fourth quarter of 2026, pending bankruptcy court and antitrust approvals.
• ▪PTC Therapeutics agreed to acquire Sangamo Therapeutics' experimental Fabry disease gene therapy, ST-920, for $111 million in cash up front.
• ▪PTC Therapeutics is responsible for up to $100 million more in milestone payments, including $80 million for accelerated FDA approval and $20 million for full clearance of ST-920.

Sangamo bankruptcy asset auction

• ▪Astellas Pharma served as the stalking horse bidder for Sangamo Therapeutics' Fabry program with a baseline bid of $50 million, including $25 million up front and $25 million in milestones.
• ▪Eli Lilly won a separate part of the Sangamo Therapeutics bankruptcy auction by agreeing to pay $50 million in cash for certain platform technologies in neurology and the preclinical program ST-506.
• ▪As of June 30, 2026, Sangamo Therapeutics reported $153 million in total assets and $130.4 million in total liabilities.
• ▪Sangamo Therapeutics filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware under case number 26-10989 in June 2026.

Fabry disease gene therapy

• ▪In an open-label Phase 1/2 study, Sangamo Therapeutics reported that ST-920 showed improvement in kidney function measures at 52 weeks in adults with Fabry disease.
• ▪ST-920, also known as isaralgagene civaparvovec, is designed as a one-time infusion that delivers a functioning copy of the GLA gene to liver cells using an adeno-associated virus.
• ▪Fabry disease is an inherited metabolic disorder caused by mutations in the GLA gene, which leads to a deficiency of the enzyme alpha-galactosidase A and affects an estimated 11,000 people in the U.S.

ST-920 regulatory submission timeline

• ▪PTC Therapeutics plans to complete the rolling FDA submission for ST-920 in the fourth quarter of 2026, with a potential commercial launch targeted for 2027.
• ▪Sangamo Therapeutics initiated a rolling submission for accelerated FDA approval of ST-920 in December 2025.
• ▪PTC Therapeutics stated that its regulatory submission plan uses a 52-week trial for initial accelerated FDA approval, with 104-week results set to support traditional approval.

Analyst acquisition risk assessment

• ▪RBC Capital Markets analyst Brian Abrahams noted that the risk of gene therapy being out of favor is mitigated by the low cost and synergies with PTC Therapeutics' rare disease business.
• ▪Leerink Partners analyst Joseph Schwartz viewed the acquisition favorably because the application is underway and PTC Therapeutics will not need to run a confirmatory study.
• ▪Jefferies analyst Faisal Khurshid characterized the acquisition as a prudent deal with low risk and strong upside, noting the Fabry disease market is worth over $2 billion.

2 sources